Navigation Links
HeartWare International, Inc. Temporary Suspension of Trading
Date:9/1/2009

FRAMINGHAM, Mass. and SYDNEY, Sept. 1 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN) today confirmed that trading of its CHESS Depositary Interests ("CDIs") on the Australian Securities Exchange ("ASX") was temporarily suspended for the reasons stated below. In consequence, trading of the Company's common stock on NASDAQ is also temporarily suspended. Based on discussions with representatives of NASDAQ and the ASX, the Company believes that trading will recommence on both the ASX and NASDAQ exchanges tomorrow (September 2, 2009).

On August 14, 2009, the Company filed its Quarterly Report on Form 10-Q for the 3 and 6 month period ended June 30, 2009 ("Quarterly Report") with both the ASX and the Securities and Exchange Commission. The Quarterly Report is prepared under U.S. generally accepted accounting principles and otherwise in compliance with the requirements of the Securities Exchange Act of 1934, as amended.

As permitted by ASX Listing Rules, the Company is entitled to file its Quarterly Report with the ASX for the purposes of satisfying Australian financial reporting requirements. However, it is a technical requirement of the ASX Listing Rules now that HeartWare is headquartered in the United States that, in addition to the Company's US reporting obligations, the Company's independent public accountant, Grant Thornton, must provide a brief review to Australian stockholders. In filing its Quarterly Report with the ASX, this supplemental review was omitted from our filing with ASX and, in consequence, the Company's securities on the ASX have been temporarily suspended pending filing of the relevant document (with NASDAQ trading being automatically suspended in consequence). Grant Thornton's review will be completed and filed with ASX today with trading expected to resume tomorrow (September 2, 2009).

Filing of this supplemental review does not impact or otherwise affect the Company's results, operations or disclosures as set out in the Quarterly Report. The Company believes that the Quarterly Report fully complies with the requirements of the Securities Exchange Act of 1934, as amended and, in accordance with generally accepted accounting practice, that it fairly presents, in all material respects, the financial condition and results of operations of the Company as at the relevant dates.

About HeartWare International - HeartWare International develops and manufactures miniaturized implantable heart pumps, or left ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM)pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare(R) Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.

HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market.

    For further information:
    www.heartware.com                         US Investor Relations
    Howard Leibman                            Matt Clawson
    HeartWare International                   Allen & Caron Inc
    Email.  howard.leibman@heartware.com.au   Email. matt@allencaron.com
    Tel.  +61 402 440 644                     Tel. +1 949 474 4300

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the progress of clinical trials. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.

We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in "Item 1A. Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 28, 2008, and those described in other reports filed from time to time with the SEC.


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. HeartWare Appoints Timothy J. Barberich to Board of Directors
2. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
5. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
10. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
11. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):